Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD

Eikan Mishima, Shinji Fukuda, Hisato Shima, Akiyoshi Hirayama, Yasutoshi Akiyama, Yoichi Takeuchi, Noriko N. Fukuda, Takehiro Suzuki, Chitose Suzuki, Akinori Yuri, Koichi Kikuchi, Yoshihisa Tomioka, Sadayoshi Ito, Tomoyoshi Soga, Takaaki Abe

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The accumulation of uremic toxins is involved in the progression of CKD. Various uremic toxins are derived from gut microbiota, and an imbalance of gut microbiota or dysbiosis is related to renal failure. However, the pathophysiologic mechanisms underlying the relationship between the gut microbiota and renal failure are still obscure. Using an adenine-induced renal failure mouse model, we evaluated the effects of the ClC-2 chloride channel activator lubiprostone (commonly used for the treatment of constipation) onCKD. Oral administration of lubiprostone (500 mg/kg per day) changed the fecal and intestinal properties in mice with renal failure. Additionally, lubiprostone treatment reduced the elevated BUN and protected against tubulointerstitial damage, renal fibrosis, and inflammation. Gut microbiome analysis of 16S rRNA genes in the renal failure mice showed that lubiprostone treatment altered their microbial composition, especially the recovery of the levels of the Lactobacillaceae family and Prevotella genus, which were significantly reduced in the renal failure mice. Furthermore, capillary electrophoresismass spectrometry-based metabolome analysis showed that lubiprostone treatment decreased the plasma level of uremic toxins, such as indoxyl sulfate and hippurate, which are derived from gut microbiota, and a more recently discovered uremic toxin, trans-aconitate. These results suggest that lubiprostone ameliorates the progression of CKD and the accumulation of uremic toxins by improving the gut microbiota and intestinal environment.

Original languageEnglish
Pages (from-to)1787-1794
Number of pages8
JournalJournal of the American Society of Nephrology
Volume26
Issue number8
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Adenine
Renal Insufficiency
Lactobacillaceae
Aconitic Acid
Indican
Dysbiosis
Prevotella
Metabolome
Blood Urea Nitrogen
Constipation
Therapeutics
rRNA Genes
Oral Administration
Lubiprostone
Gastrointestinal Microbiome
Spectrum Analysis
Fibrosis
Inflammation
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. / Mishima, Eikan; Fukuda, Shinji; Shima, Hisato; Hirayama, Akiyoshi; Akiyama, Yasutoshi; Takeuchi, Yoichi; Fukuda, Noriko N.; Suzuki, Takehiro; Suzuki, Chitose; Yuri, Akinori; Kikuchi, Koichi; Tomioka, Yoshihisa; Ito, Sadayoshi; Soga, Tomoyoshi; Abe, Takaaki.

In: Journal of the American Society of Nephrology, Vol. 26, No. 8, 01.08.2015, p. 1787-1794.

Research output: Contribution to journalArticle

Mishima, E, Fukuda, S, Shima, H, Hirayama, A, Akiyama, Y, Takeuchi, Y, Fukuda, NN, Suzuki, T, Suzuki, C, Yuri, A, Kikuchi, K, Tomioka, Y, Ito, S, Soga, T & Abe, T 2015, 'Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD', Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1787-1794. https://doi.org/10.1681/ASN.2014060530
Mishima, Eikan ; Fukuda, Shinji ; Shima, Hisato ; Hirayama, Akiyoshi ; Akiyama, Yasutoshi ; Takeuchi, Yoichi ; Fukuda, Noriko N. ; Suzuki, Takehiro ; Suzuki, Chitose ; Yuri, Akinori ; Kikuchi, Koichi ; Tomioka, Yoshihisa ; Ito, Sadayoshi ; Soga, Tomoyoshi ; Abe, Takaaki. / Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. In: Journal of the American Society of Nephrology. 2015 ; Vol. 26, No. 8. pp. 1787-1794.
@article{5a86477117454b8c89095d3ce5d653c3,
title = "Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD",
abstract = "The accumulation of uremic toxins is involved in the progression of CKD. Various uremic toxins are derived from gut microbiota, and an imbalance of gut microbiota or dysbiosis is related to renal failure. However, the pathophysiologic mechanisms underlying the relationship between the gut microbiota and renal failure are still obscure. Using an adenine-induced renal failure mouse model, we evaluated the effects of the ClC-2 chloride channel activator lubiprostone (commonly used for the treatment of constipation) onCKD. Oral administration of lubiprostone (500 mg/kg per day) changed the fecal and intestinal properties in mice with renal failure. Additionally, lubiprostone treatment reduced the elevated BUN and protected against tubulointerstitial damage, renal fibrosis, and inflammation. Gut microbiome analysis of 16S rRNA genes in the renal failure mice showed that lubiprostone treatment altered their microbial composition, especially the recovery of the levels of the Lactobacillaceae family and Prevotella genus, which were significantly reduced in the renal failure mice. Furthermore, capillary electrophoresismass spectrometry-based metabolome analysis showed that lubiprostone treatment decreased the plasma level of uremic toxins, such as indoxyl sulfate and hippurate, which are derived from gut microbiota, and a more recently discovered uremic toxin, trans-aconitate. These results suggest that lubiprostone ameliorates the progression of CKD and the accumulation of uremic toxins by improving the gut microbiota and intestinal environment.",
author = "Eikan Mishima and Shinji Fukuda and Hisato Shima and Akiyoshi Hirayama and Yasutoshi Akiyama and Yoichi Takeuchi and Fukuda, {Noriko N.} and Takehiro Suzuki and Chitose Suzuki and Akinori Yuri and Koichi Kikuchi and Yoshihisa Tomioka and Sadayoshi Ito and Tomoyoshi Soga and Takaaki Abe",
year = "2015",
month = "8",
day = "1",
doi = "10.1681/ASN.2014060530",
language = "English",
volume = "26",
pages = "1787--1794",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD

AU - Mishima, Eikan

AU - Fukuda, Shinji

AU - Shima, Hisato

AU - Hirayama, Akiyoshi

AU - Akiyama, Yasutoshi

AU - Takeuchi, Yoichi

AU - Fukuda, Noriko N.

AU - Suzuki, Takehiro

AU - Suzuki, Chitose

AU - Yuri, Akinori

AU - Kikuchi, Koichi

AU - Tomioka, Yoshihisa

AU - Ito, Sadayoshi

AU - Soga, Tomoyoshi

AU - Abe, Takaaki

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The accumulation of uremic toxins is involved in the progression of CKD. Various uremic toxins are derived from gut microbiota, and an imbalance of gut microbiota or dysbiosis is related to renal failure. However, the pathophysiologic mechanisms underlying the relationship between the gut microbiota and renal failure are still obscure. Using an adenine-induced renal failure mouse model, we evaluated the effects of the ClC-2 chloride channel activator lubiprostone (commonly used for the treatment of constipation) onCKD. Oral administration of lubiprostone (500 mg/kg per day) changed the fecal and intestinal properties in mice with renal failure. Additionally, lubiprostone treatment reduced the elevated BUN and protected against tubulointerstitial damage, renal fibrosis, and inflammation. Gut microbiome analysis of 16S rRNA genes in the renal failure mice showed that lubiprostone treatment altered their microbial composition, especially the recovery of the levels of the Lactobacillaceae family and Prevotella genus, which were significantly reduced in the renal failure mice. Furthermore, capillary electrophoresismass spectrometry-based metabolome analysis showed that lubiprostone treatment decreased the plasma level of uremic toxins, such as indoxyl sulfate and hippurate, which are derived from gut microbiota, and a more recently discovered uremic toxin, trans-aconitate. These results suggest that lubiprostone ameliorates the progression of CKD and the accumulation of uremic toxins by improving the gut microbiota and intestinal environment.

AB - The accumulation of uremic toxins is involved in the progression of CKD. Various uremic toxins are derived from gut microbiota, and an imbalance of gut microbiota or dysbiosis is related to renal failure. However, the pathophysiologic mechanisms underlying the relationship between the gut microbiota and renal failure are still obscure. Using an adenine-induced renal failure mouse model, we evaluated the effects of the ClC-2 chloride channel activator lubiprostone (commonly used for the treatment of constipation) onCKD. Oral administration of lubiprostone (500 mg/kg per day) changed the fecal and intestinal properties in mice with renal failure. Additionally, lubiprostone treatment reduced the elevated BUN and protected against tubulointerstitial damage, renal fibrosis, and inflammation. Gut microbiome analysis of 16S rRNA genes in the renal failure mice showed that lubiprostone treatment altered their microbial composition, especially the recovery of the levels of the Lactobacillaceae family and Prevotella genus, which were significantly reduced in the renal failure mice. Furthermore, capillary electrophoresismass spectrometry-based metabolome analysis showed that lubiprostone treatment decreased the plasma level of uremic toxins, such as indoxyl sulfate and hippurate, which are derived from gut microbiota, and a more recently discovered uremic toxin, trans-aconitate. These results suggest that lubiprostone ameliorates the progression of CKD and the accumulation of uremic toxins by improving the gut microbiota and intestinal environment.

UR - http://www.scopus.com/inward/record.url?scp=84938928604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938928604&partnerID=8YFLogxK

U2 - 10.1681/ASN.2014060530

DO - 10.1681/ASN.2014060530

M3 - Article

C2 - 25525179

AN - SCOPUS:84938928604

VL - 26

SP - 1787

EP - 1794

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -